How should long‑COVID‑associated shortness of breath be treated in a 62‑year‑old male patient?

Treatment of Long COVID with Shortness of Breath in a 62-Year-Old Male

For a 62-year-old male with long COVID-associated shortness of breath, prioritize symptom-based supportive care with careful activity pacing to avoid postexertional malaise, while avoiding traditional exercise programs that can worsen symptoms in 75% of patients. 1

Initial Assessment and Diagnostic Workup

Before initiating treatment, complete a targeted evaluation to rule out alternative causes and characterize the dyspnea:

• Pulmonary function testing (PFT) with particular attention to diffusion capacity for carbon monoxide (DLCO), as impairment occurs in 10-80% of patients depending on acute disease severity 1
• Basic laboratory assessment including C-reactive protein, complete blood count, kidney and liver function tests 1
• Cardiac evaluation with troponin, CPK-MB, and B-type natriuretic peptide given the respiratory symptoms 1
• Oxygen saturation monitoring and blood gas analysis if desaturation is present 1
• Chest imaging (CT scan) if clinically indicated to detect structural abnormalities or microclots 1

Standard test results are often normal in long COVID patients despite significant symptoms, so normal findings do not exclude the diagnosis 1

Core Management Strategy

Energy Conservation and Activity Pacing (Critical First-Line Approach)

Implement strict activity pacing protocols immediately - this is the most important intervention to prevent symptom worsening 1, 2:

• Teach the patient to stay within their "energy envelope" and avoid pushing through fatigue
• Monitor for postexertional malaise (PEM)/postexertional symptom exacerbation (PESE), where symptoms worsen 12-48 hours after activity 2
• Avoid traditional exercise programs or pulmonary rehabilitation that encourages progressive exertion, as physical activity worsened symptoms in 75% of long COVID patients with less than 1% showing improvement 1

Symptom-Specific Pharmacological Options

For respiratory symptoms and associated manifestations:

• H1 and H2 antihistamines (particularly famotidine) following mast cell activation syndrome protocols to address wide-ranging symptoms including dyspnea 1
• Beta-blockers if dysautonomia or POTS symptoms accompany the dyspnea (tachycardia, orthostatic intolerance) 1
• Low-dose naltrexone for neuroinflammation and general symptom management, showing promise across multiple long COVID symptoms 1

Anticoagulation Consideration

If microclotting is suspected (particularly with persistent dyspnea and normal standard testing):

• Consider anticoagulant therapy, as one study showed complete symptom resolution in all 24 patients receiving triple anticoagulant therapy 1
• This requires specialist consultation and careful risk-benefit assessment

Emerging Evidence-Based Interventions

Cognitive behavioral therapy (CBT) delivered online probably reduces fatigue and improves concentration with moderate certainty evidence 3

Combined physical and mental health rehabilitation program (online, supervised) probably improves overall health, reduces depression, and enhances quality of life, with 161 more patients per 1000 experiencing meaningful improvement 3

If aerobic exercise is attempted (only after careful assessment for PEM/PESE risk), intermittent aerobic exercise 3-5 times weekly for 4-6 weeks is superior to continuous exercise for improving physical function 3

Supplements Worth Considering

• Coenzyme Q10 and D-ribose have shown promise in both long COVID and ME/CFS 1

Antiviral Consideration

Paxlovid showed a 25% reduction in long COVID incidence when used for acute COVID-19, and case reports suggest benefit for established long COVID 1. Consider discussing with the patient if symptoms are severe and progressive.

Critical Pitfalls to Avoid

Do not prescribe graded exercise therapy or standard pulmonary rehabilitation that encourages "pushing through" symptoms - this is the most common and harmful error in long COVID management 1, 2

Validate the patient's experience explicitly - many patients have had symptoms dismissed, which worsens outcomes 2

Recognize that this is likely a chronic condition - 85% of patients with symptoms at 2 months still had symptoms at 1 year, and ME/CFS diagnoses are generally lifelong 1

Prognosis and Follow-Up

The natural history shows that respiratory abnormalities may improve over time, with DLCO impairment decreasing from 50-70% at 3 months to lower rates at 6-12 months in hospitalized patients 1. However, complete resolution is uncommon 1. Regular monitoring of symptoms and functional status is essential, with adjustments to the management plan based on response 2, 4.